Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $52.8 million.

  • Catalyst Pharmaceuticals' Net Income towards Common Stockholders rose 2027.85% to $52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $217.1 million, marking a year-over-year increase of 6579.36%. This contributed to the annual value of $163.4 million for FY2024, which is 17443.4% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Net Income towards Common Stockholders stood at $52.8 million for Q3 2025, which was up 2027.85% from $52.1 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' Net Income towards Common Stockholders registered a high of $56.7 million during Q1 2025, and its lowest value of -$30.8 million during Q3 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Net Income towards Common Stockholders value was $23.3 million (recorded in 2024), while the average stood at $26.7 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first plummeted by 23523.83% in 2023, then skyrocketed by 24264.73% in 2024.
  • Quarter analysis of 5 years shows Catalyst Pharmaceuticals' Net Income towards Common Stockholders stood at $9.3 million in 2021, then soared by 173.62% to $25.5 million in 2022, then decreased by 9.82% to $23.0 million in 2023, then skyrocketed by 141.33% to $55.4 million in 2024, then decreased by 4.78% to $52.8 million in 2025.
  • Its last three reported values are $52.8 million in Q3 2025, $52.1 million for Q2 2025, and $56.7 million during Q1 2025.